What is the appropriate tenecteplase dosage for acute myocardial infarction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tenecteplase Dosing for Acute Myocardial Infarction

For acute myocardial infarction (STEMI), administer tenecteplase as a single intravenous weight-based bolus: 30 mg for weight <60 kg; 35 mg for 60-69 kg; 40 mg for 70-79 kg; 45 mg for 80-89 kg; and 50 mg for ≥90 kg. 1

Weight-Based Dosing Algorithm

The dosing is straightforward and based on 10-kg weight bands 1, 2:

  • <60 kg: 30 mg IV bolus
  • 60-69 kg: 35 mg IV bolus
  • 70-79 kg: 40 mg IV bolus
  • 80-89 kg: 45 mg IV bolus
  • ≥90 kg: 50 mg IV bolus

This represents a single bolus injection administered over 5 seconds, which is substantially simpler than alteplase's 90-minute weight-based infusion protocol 1, 3.

Clinical Context and Timing

Tenecteplase should be administered when fibrinolytic therapy is indicated for STEMI—specifically when primary PCI cannot be performed within 120 minutes of first medical contact and symptoms have been present for less than 12 hours 1. The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines explicitly recommend fibrin-specific agents like tenecteplase over non-fibrin-specific agents due to superior patency rates (85% achieving TIMI 2 or 3 flow at 90 minutes) and reduced immunogenicity 1, 2.

Important Distinctions from Stroke Dosing

Critical caveat: The STEMI dosing differs substantially from acute ischemic stroke dosing. For stroke, tenecteplase is dosed at 0.25 mg/kg (maximum 25 mg) 4. The STEMI doses are approximately double the stroke doses—this reflects different pathophysiology and evidence bases. Using stroke dosing for MI or vice versa would constitute a significant medication error.

Practical Advantages

Tenecteplase offers several operational benefits over alteplase for STEMI: single bolus administration reduces dosing complexity and potential for errors, enables faster treatment delivery, and simplifies pre-hospital administration by paramedics in rural/remote settings 1, 5. The ASSENT-2 trial demonstrated equivalent 30-day mortality to alteplase with fewer non-cerebral bleeding complications and reduced transfusion requirements 6, 7.

Contraindications

Absolute contraindications include any prior intracranial hemorrhage, known structural cerebral vascular lesions, known malignant intracranial neoplasm, ischemic stroke within 3 months (except acute ischemic stroke within 4.5 hours), suspected aortic dissection, active bleeding or bleeding diathesis, significant closed-head or facial trauma within 3 months, intracranial or intraspinal surgery within 2 months, and severe uncontrolled hypertension (SBP >180 mm Hg or DBP >110 mm Hg unresponsive to therapy) 1, 2.

Post-Administration Management

After tenecteplase administration, immediate transfer to a PCI-capable center is mandatory 2. Early angiography between 2-24 hours with intent to perform PCI reduces rates of death or MI—this "pharmacoinvasive" strategy represents the standard of care 2. If there is suspected failed reperfusion, immediate rescue PCI is indicated 2.

Key Safety Consideration

The ASSENT-4 PCI trial was prematurely terminated due to worse outcomes when tenecteplase was administered immediately before planned primary PCI (with anticipated 1-3 hour delay). The 90-day composite endpoint of death/cardiogenic shock/CHF was 18.6% with tenecteplase plus PCI versus 13.4% with PCI alone 8. Therefore, do not administer tenecteplase if primary PCI can be performed promptly without significant delay—reserve fibrinolytic therapy for situations where the 120-minute FMC-to-device time cannot be achieved 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.